Enliven Pharma - ELVN Quarterly EPS earnings growth

Corporate company logo of Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics specializes in developing precision molecules to combat resistant tumors. The quarterly EPS growth snapshot visualizes the movement of global investments, where the value of -9.20 represents the latest figure. Success is based on robust R&D potential, streamlined biosample logistics, and strict adherence to environmental regulations regarding the disposal of laboratory waste.

enliventherapeutics.com (ELVN) Year-over-year earnings per one share growth for the last 12 months: for the period 04/28/2023 - 11/18/2026

Analytical breakdowns for Enliven Therapeutics

- share price and consensus valuation forecast:
Fundamental company valuation:enliventherapeutics.com - ELVN
Flagship merchandise of enliventherapeutics.com

The investment attractiveness of Enliven Therapeutics (ELVN) is based on expectations for breakthrough developments in the field of selective kinase inhibitors. This metric measures the rate of change in quarterly earnings per share, reflecting the efficiency of cost management relative to revenue. By analyzing the quarterly EPS growth rate, an investor identifies the gap between operating expenses and actual income. For the biotech sector with aggressive clinical trials, this indicator signals financial stability during pipeline scaling. Positive dynamics confirm the capitalization of innovations and the growth of the business's intrinsic value.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Therapeutics) - Quarterly EPS earnings growth|Quarterly EPS earnings growth kymeratx.com|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences, Inc. (IDYA)|ORIC (ORIC Pharmaceuticals, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics Inc)|Net earnings per share growth for the trailing year Nurix Pharma|Tyra Biosciences Inc - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (immuneering.com) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Tx CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc. - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Cyclacel Pharmaceuticals - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics Inc - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months glycomimetics.com GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks (SWTX)